The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment.
- Authors
- AndrΓ©, Aurore; Gonthier, Marie-Paule
- Year
- 2010
- Journal
- The international journal of biochemistry & cell biology
- PMID
- 20541029
- DOI
- 10.1016/j.biocel.2010.06.002
Obesity and cardiometabolic risk continue to be major public health concerns. A better understanding of the physiopathological mechanisms leading to obesity may help to identify novel therapeutic targets. The endocannabinoid system discovered in the early 1990s is believed to influence body weight regulation and cardiometabolic risk factors. This article aims to review the literature on the endocannabinoid system including the biological roles of its major components, namely, the cannabinoid receptors, their endogenous ligands the endocannabinoids and the ligand-metabolising enzymes. The review also discusses evidence that the endocannabinoid system constitutes a new physiological pathway occurring in the central nervous system and peripheral tissues that has a key role in the control of food intake and energy expenditure, insulin sensitivity, as well as glucose and lipid metabolism. Based on the important finding that there is a close association between obesity and the hyperactivity of the endocannabinoid system, interest in blocking stimulation of this pathway to aid weight loss and reduce cardiometabolic risk factor development has become an important area of research. Among the pharmacological strategies proposed, the antagonism of the cannabinoid receptors has been particularly investigated and several clinical trials have been conducted. One challenging pharmacological task will be to target the endocannabinoid system in a more selective, and hence, safe way. As the management of obesity also requires lifestyle modifications in terms of healthy eating and physical activity, the targeting of the endocannabinoid system may represent a novel approach for a multifactorial therapeutic strategy.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Anti-obesity effects of Oleoylethanolamide: Modulation of mitochondrial bioenergetics, endocannabinoidome and gut microbiome. | Cimmino F et al. | β | 2025 | β |
| Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB<sub>2</sub> Agonists with Neuroprotective Effects. | GioΓ©-Gallo C et al. | β | 2025 | β |
| Role of interplay between endocannabinoids and neuropeptides in pathogenesis and therapy of depressive and anxiety disorders. | GoΕyszny M et al. | β | 2025 | β |
| A comprehensive review of genetic causes of obesity. | ConcepciΓ³n-Zavaleta MJ et al. | β | 2024 | β |
| Changes in plasma endocannabinoids concentrations correlate with 18F-FDG PET/MR uptake in brown adipocytes in humans. | Maliszewska K et al. | β | 2023 | β |
| Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock? | BarrΓ© T et al. | β | 2023 | β |
| The Current and Potential Application of Medicinal Cannabis Products in Dentistry. | Lowe H et al. | β | 2021 | β |
| Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB<sub>1</sub>R Inverse Agonists. | Zhang YM et al. | β | 2020 | β |
| Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol. | Bielawiec P et al. | β | 2020 | β |
| Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity. | Simcocks AC et al. | β | 2019 | β |
| Oleoylethanolamide: A novel pharmaceutical agent in the management of obesity-an updated review. | Laleh P et al. | β | 2019 | β |
| CB1 receptors in the paraventricular nucleus of the hypothalamus modulate the release of 5-HT and GABA to stimulate food intake in rats. | Cruz-MartΓnez AM et al. | β | 2018 | β |
| Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors. | Bystrowska B et al. | β | 2018 | β |
| New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents. | Sharma MK et al. | β | 2018 | β |
| Orexin-A and endocannabinoid signaling regulate glucose-responsive arcuate nucleus neurons and feeding behavior in obese rats. | Yang D et al. | β | 2018 | β |
| Cannabis in fat: high hopes to treat obesity. | Hawkins MN et al. | β | 2017 | β |
| Metabolic Profiling of CB1 Neutral Antagonists. | Seltzman HH et al. | β | 2017 | β |
| Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. | Palma E et al. | β | 2016 | β |
| Hydroxytyrosol Inhibits Cannabinoid CB1 Receptor Gene Expression in 3T3-L1 Preadipocyte Cell Line. | Tutino V et al. | β | 2016 | β |
| Cannabinoid receptor 1 is a major mediator of renal fibrosis. | Lecru L et al. | β | 2015 | β |
| Dissecting the cannabinergic control of behavior: The where matters. | Busquets-Garcia A et al. | β | 2015 | β |
| Mitochondrial ADP/ATP exchange inhibition: a novel off-target mechanism underlying ibipinabant-induced myotoxicity. | Schirris TJ et al. | β | 2015 | β |
| Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459. | Goonawardena AV et al. | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. | Sharma MK et al. | β | 2014 | β |
| Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. | Verty AN et al. | β | 2013 | β |
| Chronic endocannabinoid system stimulation induces muscle macrophage and lipid accumulation in type 2 diabetic mice independently of metabolic endotoxaemia. | Geurts L et al. | β | 2013 | β |
| Development of fluorinated CB(2) receptor agonists for PET studies. | Lueg C et al. | β | 2013 | β |
| Distinct and replicable genetic risk factors for acute respiratory distress syndrome of pulmonary or extrapulmonary origin. | Tejera P et al. | β | 2012 | β |
| Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. | Ansari JA et al. | β | 2012 | β |
| Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis. | Rasmussen EB et al. | β | 2012 | β |
| Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. | Murumalla R et al. | β | 2011 | β |
| Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. | Marco EM et al. | β | 2011 | β |
| Etiologies of obesity in children: nature and nurture. | Skelton JA et al. | β | 2011 | β |
| ISSFAL 2010 dinner debate: healthy fats for healthy hearts - annotated report of a scientific discussion. | Nettleton JA et al. | β | 2011 | β |
| Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. | Ward SJ et al. | β | 2011 | β |
| The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. | Cable JC et al. | β | 2011 | β |